Pancreatic ductal adenocarcinoma (PDAC) is highly lethal, with treatment effectiveness, including immunotherapy, limited by immunosuppressive tumor microenvironment. This study identifies TNK2/ACK1 as a driver of immune evasion in pancreatic cancer via STAT5A-HVEM signaling that disables CD8⁺ T cells while TNK2 inhibition restores antitumor immunity and synergizes with anti-PD-1 and chemotherapy in PDAC models.
- Chao Wu
- Weishuai Liu
- Jihui Hao